Marinomed Biotech AG, a Vienna-based biopharmaceutical company, has reported its first-half 2025 financial results and executed a capital-increase program, raising approximately €1.08 million to support ongoing research and development projects.

Marinomed Biotech AG has made a strategic leap forward with a partnership with a Swiss pharmaceutical giant, positioning the company for international success and growth amidst market volatility.

Marinomed Biotech AG, a Vienna-based biopharmaceutical company, has made recent announcements and is navigating a challenging market, but remains focused on developing innovative immunological and antiviral therapies.

Marinomed Biotech AG, a biopharmaceutical company, navigates the Vienna Stock Exchange with its shares fluctuating between 2-17.9 EUR, amidst market volatility and a focus on innovative immunological and antiviral treatments.

Marinomed Biotech AG is gearing up for its 8th Annual General Meeting on June 11, 2025, where the company will outline its future plans and strategies for navigating the pharmaceutical industry.

Marinomed Biotech AG, a biopharmaceutical company, will participate in the 15th International Investment Forum to showcase its innovative therapies and engage with potential investors.